TABLE 1.
Summary of Nanoconjugates, their Abbreviations, and Physicochemical Characterization
| imaging and treatment agents | abbreviations | hydrodynamic diameter (nm)a |
zeta potential (mV)b |
|---|---|---|---|
| poly(β-L-malic acid) | PMLA | 6.6 (±0.1) | −22.9 (±1.7) |
| P/MEA(4%)/Gd-DOTA(10–12%)c | Preconjugate-1 | 8.8 (±0.7) | −16.8 (±1.8) |
| P/cetuximab(0.12%)/MsTfR-mAb(0.12%)/Alexa-680(1%)/Gd-DOTA(10–12%) | P/Gd-DOTA/cetuximab/MsTfR-mAb/Alexa-680 | 16.0 (±1.5) | −8.7 (±1.2) |
| P/trastuzumab(0.12%)/MsTfR-mAb(0.12%)/Alexa-680(1%)/Gd-DOTA(10–12%) | P/Gd-DOTA/trastuzumab/MsTfR-mAb/Alexa-680 | 16.3 (±1.6) | −6.9 (±1.1) |
| P/mPEG(5%)/LOEt(40%)/MEA(4–6%) | Preconjugate-2 | 8.1 (±0.5) | −8.5 (±1.2) |
| P/mPEG(5%)/LOEt(40%)/HuTfR-mAb(0.2%)/MsTfR-mAb(0.2%)/EGFR-AON(2–4%) | P/Hu/MsTfR-mAb/EGFR-AON | 15.7 (±2.0) | −2.6 (±0.8) |
| P/mPEG(5%)/LOEt(40%)/trastuzumab(0.2%)/MsTfR-mAb(0.2%)/HER2-AON(3–4%) | P/trastuzumab/MsTfR-mAb/HER2-AON | 15.7 (±2.0) | −4.1 (±0.8) |
a
Hydrodynamic diameter by number distribution at 25 °C measured in PBS at a concentration of 2 mg/mL, calculated from DLS data by the Malvern Zetasizer software (Malvern Instruments, Malvern, UK), which assumes spherical shapes of particles.
b
Zeta potential at 25 °C in an aqueous solution of 10 mM NaCl at 150 mV.
c
Composition of nanoconjugates; percentage refers to total number (100%) of pendant carboxyl groups in unsubstituted PMLA.